Cross-disciplinary research opportunity for training in AD/ADRD science (CROSSROADS)
- Institution
- UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL
- Principal investigator
- Tatjana Rundek
- Funding
- $559K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
There are more than 6 million cases of Alzheimer’s disease (AD) reported in the US, of which 10% live in Florida, making Florida the second leading state with the highest prevalence of AD. This number will rapidly grow, creating an urgent need to address this AD/ADRD public health crisis. This crisis is further exacerbated by a massive shortage of trained physicians and scientists caring for this vulnerable population. The proposed T32 program: Cross-disciplinary Research Opportunity for Training in AD/ADRD Science (CrossROADS) is a 2-year program at the University of Miami (UM), leveraging our experience implementing academic training programs over the past 20 years. The overall goal is to increase the number of AD/ADRD investigators-leaders in cross-disciplinary clinical and translational research, who can rapidly translate, implement and disseminate discoveries to practice and community. CrossROADS graduates will be capable to address the health challenges of AD/ADRD patients and caregivers we serve through team science and collaborations in partnerships with AD/ADRD community partners and stakeholders. CrossROADS is designed to select outstanding clinical, biomedical, and psychosocial science postdoctoral trainees, and provide a high-quality, research and leadership training program for the next generation of AD/ADRD scientists. The Objectives are to: (1) Develop and administer a 2-year cross-disciplinary research training program in AD/ADRD for 12 postdoctoral candidates; (2) Provide an evidence-informed mentorship through collaborative and individually tailored cross-disciplinary mentorship. Each trainee will be assigned to a mentorship team comprised of an experienced Primary Mentor, Peer Mentor, and as required, additional clinical or career development mentors to facilitate trainees’ socialization and integration in the academic cross-disciplinary research environment; and (3) Create opportunities to transition to career independence through career advising, coaching and sponsorship, strategies to enhance career visibility and competitiveness, and professional development with leadership training. We will integrate our trainees in our successful institutional training programs and collaborative environment fostering team science. The Leadership Team will rigorously evaluate the impact of the CrossROADS program on training of independent cross-disciplinary scientists-leaders, their mastery of core competencies, and their impact on health in AD/ADRD communities.
Research team
- James E GalvinPI
- Girardin Jean-LouisPI
- Tatjana RundekPI
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Institute for Molecular MedicineNot yet scored
FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.
Michael G Agadjanyan · $5.3M · 2025–2030
- NIH · Institute for Molecular MedicineNot yet scored
IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Michael G Agadjanyan · $1.8M · 2024–2029
- NIH · Eip Pharma, Inc.Not yet scored
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
John Alam · $6.1M · 2023–2026